Eligible patients must have IPSS6 low‐ or intermediate‐1‐risk MDS without RS or del(5q) and Hb levels <9 g/dL and defined ineligible for or having failed ESA therapy in the absence of disease progression. Here, GSTM1 is linked to myelodysplastic syndrome.